Glioma Growth Inhibition In Vitro and In Vivo by Single Chain Variable Fragments of the Transferrin Receptor Conjugated to Survivin Small Interfering RNA
Free accessResearch articleFirst published online October, 2011
Glioma Growth Inhibition In Vitro and In Vivo by Single Chain Variable Fragments of the Transferrin Receptor Conjugated to Survivin Small Interfering RNA
Inhibition of survivin by small interfering RNA (siRNA) can delay glioma growth. To enhance the effect of survivin-siRNA on intercranial glioma, a conjugate of siRNA-survivin and single-chain variable fragment (scFv) of the transferrin receptor (TfR) was constructed and its effects assessed in vitro and in vivo. Survivin-siRNA and the survivin-siRNA/scFv-TfR conjugate were constructed and used successfully to inhibit glioma U87 cell proliferation and enhance apoptosis in vitro. The molecular constructs were administered to an established U87 orthotopic mouse model. Western blot analysis and immunohistochemistry of the glioma tissues showed that survivin protein levels were strongly suppressed by the survivin-siRNA/scFv-TfR conjugate in vivo. Furthermore, survivin-siRNA/scFv-TfR prolonged the survival time of mice more than survivin-siRNA. In conclusion, the survivin-siRNA/scFv-TfR conjugate efficiently enhanced the effects of survivin-siRNA on glioma suppression in vivo, confirming the applicability of antibody-targeted molecular therapies for treating human brain tumours.
NakadaMNakadaSDemuthT: Molecular targets of glioma invasion. Cell Mol Life Sci2007; 64: 458–478.
2.
WenPYKesariS: Malignant gliomas in adults. N Engl J Med2008; 359: 492–507.
3.
ZimmermannTSLeeACAkincA: RNAi-mediated gene silencing in non-human primates. Nature2006; 441: 111–114.
4.
AkhavanDCloughesyTFMischelPS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol2010; 12: 882–889.
5.
BoadoRJ: RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx2005; 2: 139–150.
6.
ChakravartiANollEBlackPM: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol2002; 20: 1063–1068.
7.
AltieriDC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer2003; 3: 46–54.
8.
AltieriDC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer2008; 8: 61–70.
9.
KajiwaraYYamasakiFHamaS: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer2003; 97: 1077–1083.
10.
MitaACMitaMMNawrockiST: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res2008; 14: 5000–5005.
11.
YangHFuJHHuY: Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells. J Int Med Res2008; 36: 734–747.
12.
LiuQFuHXingR: Survivin knockdown combined with apoptin overexpression inhibits cell growth significantly. Cancer Biol Ther2008; 7: 1053–1060.
13.
WangYZhuHQuanL: Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther2005; 4: 974–978.
14.
LiQXZhaoJLiuJY: Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther2006; 5: 860–866.
15.
PardridgeWM: Drug and gene delivery to the brain: the vascular route. Neuron2002; 36: 555–558.
16.
PardridgeWM: shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev2007; 59: 141–152.
17.
JefferiesWABrandonMRHuntSV: Transferrin receptor on endothelium of brain capillaries. Nature1984; 312: 162–163.
18.
ZhangYPardridgeWM: Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem2001; 76: 1597–1600.
19.
QianZMLiHSunH: Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev2002; 54: 561–587.
20.
WangJTianSPetrosRA: The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc2010; 132: 11306–11313.
21.
KapplerMBacheMBartelF: Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther2004; 11: 186–193.
22.
LiJYSugimuraKBoadoRJ: Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein. Protein Eng1999; 12: 787–796.
23.
XuLTangWHHuangCC: Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med2001; 7: 723–734.
24.
SuhWChungJKParkSH: Anti-JL1 antibody-conjugated poly (L-lysine) for targeted gene delivery to leukemia T cells. J Control Release2001; 72: 171–178.
25.
KanoAMoriyamaKYamanoT: Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA. J Control Release2011; 149: 2–7.
26.
WilliamsNSGaynorRBScogginS: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res2003; 9: 931–946.
27.
LiuWSYanHJQinRY: siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci2009; 54: 89–96.
28.
LaquintanaVTrapaniADenoraN: New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv2009; 6: 1017–1032.
29.
PardridgeWM: Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv2003; 3: 90–105.
30.
PirolloKFZonGRaitA: Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther2006; 17: 117–124.
